Rennova Health Inc (RNVA)

[nfrequent]

Take note of the 01/11 amendmend to the insider trading plan/prospectus. If the selling shareholder holds through a QX/Nasdaq level uplisting, beautiful. If the selling shareholder decides to sell sometime in between, the selling shareholder still has to sell at .00014. The RNVA priority has been on reducing and restructuring debt, greatly improving the current balance sheet AND forward earnings. It's a dilemma though, debt reduction or buyback cheap (meaning before the stock runs). Solution: The 01/11 amendment locked in a buyback at .00014.

Another buyback? Maybe, but debt reduction should still be the priority because it fundementally adds as more shareholder value than a buyback by way of interest savings, with over $2 million per year in interest savings already generated through Q3 '23 from debt reduction and restructuring.